METHOD FOR COMPLEX HORMONE-CHEMORADIATION TREATMENT OF LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER OF HIGH AND VERY HIGH RISK OF PROGRESSING Russian patent published in 2020 - IPC A61N5/10 A61K38/09 A61P35/00 A61K31/337 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncourology, and can be used for complex hormone-chemoradiation treatment of localized or locally advanced prostate cancer (PC) of high and very high risk of progression. Neoadjuvant hormone chemotherapy is prescribed by docetaxel in dose of 75 mg/m² intravenously once every 21 days, total 4 injections, and a hormonal preparation Degarelix 240 mg subcutaneously – starting dose, then every 28 days in a maintenance dose of 80 mg. After 4 courses of neoadjuvant hormone chemotherapy, combined radiation therapy is performed: 22-23 sessions 2 Gy to total radiation dose 44–46 Gy – remote radiation therapy, and in 2–3 weeks – high-power interstitial radiation therapy (brachytherapy) Ir¹⁹² – single radiation dose 15 Gy, further hormonal therapy is continued to total duration of 24 months.

EFFECT: method provides higher clinical effectiveness ensured by combined radiation therapy combined with hormone-chemoradiation treatment.

1 cl, 2 ex